Ischemic stroke continues to be one of the most challenging diseases in translational
neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for …

The blood-brain barrier (BBB) is formed by the endothelial cells of cerebral microvessels,
providing a dynamic interface between the peripheral circulation and the central nervous …

The founding member of the lipoprotein receptor family, low-density lipoprotein receptor
(LDLR) plays a major role in the atherogenesis through the receptor-mediated endocytosis …

Intracerebral hemorrhage following blood–brain barrier (BBB) disruption resulting from
thrombolysis of ischemic stroke with tissue plasminogen activator (tPA) remains a critical …

The LDL receptor-related protein (originally called LRP, but now referred to as LRP1) is a
large endocytic receptor that is widely expressed in several tissues. LRP1 is a member of …

Amyloid beta (Aβ) homeostasis in the brain is governed by its production and clearance
mechanisms. An imbalance in this homeostasis results in pathological accumulations of …

Thrombolytic treatment of ischemic stroke with tissue plasminogen activator (tPA) is
markedly limited owing to concerns about hemorrhagic complications and the requirement …

The transcription factor NF-κB is a key regulator of hundreds of genes involved in cell
survival and inflammation. There is ample evidence that NF-κB is activated in cerebral …

Neurovascular dysfunction is an integral part of Alzheimer disease (AD). Changes in the
brain vascular system may contribute in a significant way to the onset and progression of …

J. Neurochem.(2010) 115, 1077–1089. Abstract Low‐density lipoprotein receptor‐related
protein‐1 (LRP1), a member of the low‐density lipoprotein receptor family, has major roles …